Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
β2-glycoprotein I (β2GPI) has been identified as a 50 000 molecular weight (MW) plasma protein cofactor required for the detection of a significant proportion of so-called anti-phospholipid antibodies (aPL) such as lupus anti-coagulants (LA). The interaction of anti-β2GPI autoantibodies with neoepitopes is caused by conformational changes induced by the binding of β2GPI to lipid membranes. In addition, Anti-β2GPI antibodies are associated with thrombotic manifestations and several mechanisms have been proposed, including inhibition of the protein C anti-coagulant pathway, inhibition of fibrinolysis and cell-mediated events.